SlimBiome® Medical update

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Unflavoured SlimBiome® Medical granted medical device status and CE mark

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that OptiBiotix has achieved medical device status and a CE mark for an unflavoured version of SlimBiome® Medical. This provides a product line extension to the existing SlimBiome® Medical range which will be launched commercially in H1 2020.

The decision to launch an unflavoured version of SlimBiome® Medical allows OptiBiotix to extend its product offering and, when used in combination with taste enhancement products such as the Natural Flavour Boosters launched in Q4 2019, expands the choice of flavours available to customers at a minimal cost to OptiBiotix. The combination of the unflavoured SlimBiome® Medical with the flavour boosters also represent cost savings to OptiBiotix as the Company is not required to register new flavours individually as medical devices thus saving time and money with future line extensions. 

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are very pleased to have been granted a medical device status and a CE mark for the second time over a 12-month period (RNS: 27.11.2019 - SlimBiome® granted medical device status & CE mark). This line extension will help us convert the commercial opportunities we are working on into distribution agreements."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than 20 international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.